29969-57-1

Usage

Synthesis Reference(s)

The Journal of Organic Chemistry, 67, p. 7884, 2002 DOI: 10.1021/jo016196i

InChI:InChI=1/C9H5ClN2O2/c10-9-4-1-6-5-7(12(13)14)2-3-8(6)11-9/h1-5H

Upstream product

• 64495-55-2 6-nitroquinolin-2-ol 
• 13675-92-8 6-nitroquinoline-N-oxide 
• 22246-16-8 6-nitro-3,4-dihydro-1H-quinolin-2-one 
• 107734-23-6 4-nitro-2-vinylaniline 
• 503-38-8 trichloromethyl chloroformate 
• 19591-18-5 N-(2-iodo-4-nitrophenyl)acetamide 
• 553-03-7 3,4-dihydro-2(1H)-quinolone 
• 613-50-3 6-nitroquinoline 
• 59-31-4 2-hydroxyquinoline 
• 106-46-7 para-dichlorobenzene 
• 29969-52-6 1-methyl-6-nitroquinolin-2(1H)-one 
• 10026-13-8 phosphorus pentachloride 

Downstream Products

• 874498-17-6 (4-chloro-phenyl)-(6-nitro-[2]quinolyl)-amine 
• 860203-13-0 6-nitro-2-phenoxyquinoline 
• 238756-47-3 6-Amino-2-chloroquinoline 
• 49609-07-6 2-amino-6-nitroquinoline 
• 64495-55-2 6-nitroquinolin-2-ol 
• 77372-73-7 6-nitroquipazine 
• 914460-61-0 6-nitro-2-(3-phenyl-pyrrolidin-1-yl)-quinoline 
• 914460-53-0 cyclohexyl-methyl-(6-nitro-quinolin-2-yl)-amine 
• 914460-54-1 methyl-(6-nitro-quinolin-2-yl)-phenyl-amine 
• 914460-64-3 N-[1-(6-nitro-quinolin-2-yl)-pyrrolidin-3-yl]-benzamide 
• 936553-19-4 2-[4-benzyl-2-(hydroxymethyl)piperazin-1-yl]-6-nitroquinoline 
• 936553-18-3 2-[4-benzyl-2-(methoxymethyl)piperazin-1-yl]-6-nitroquinoline 
• 936553-20-7 2-[4-benzyl-2-(ethoxymethyl)piperazin-1-yl]-6-nitroquinoline 
• 936553-21-8 2-[4-benzyl-2-(propoxymethyl)piperazin-1-yl]-6-nitroquinoline 

Relevant academic research and scientific papers

METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS

Provided are methods for expanding stem cells and/or lineage committed progenitor cells, such as hematopoietic stems cells and/or lineage committed progenitor cells, at least in part, by using compounds that antagonize AhR. The compounds are represented by formulae (I) (II) (III) (IV), wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification. Also provided are compositions comprising stem cells and/or lineage committed progenitor cells expanded by methods disclosed herein and methods for the treatment of diseases treatable by same.

AMIDO COMPOUNDS AS AhR MODULATORS

Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification.

Visible-Light-Photocatalyzed Reductions of N-Heterocyclic Nitroaryls to Anilines Utilizing Ascorbic Acid Reductant

A photoreductive protocol utilizing [Ru(bpy)3]2+ photocatalyst, blue light LEDs, and ascorbic acid (AscH2) has been developed to reduce nitro N-heteroaryls to the corresponding anilines. Based on experimental and computational results and previous studies, we propose that the reaction proceeds via proton-coupled electron transfer between AscH2, photocatalyst, and the nitro N-heteroaryl. The method offers a green catalytic procedure to reduce, e.g., 4-/8-nitroquinolines to the corresponding aminoquinolines, substructures present in important antimalarial drugs.

A COMPOUND AND PHARMACEUTICAL COMPOUND FOR TREATMENT OF INFLAMMATORY DISEASES

The present invention relates to a pharmaceutical composition for treating inflammatory diseases, comprising: a compound represented by chemical formula I, a pharmaceutically acceptable salt thereof; a hydrate thereof; or a compound as a solvate thereof,

Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease

Disclosed herein are sulfonamide compounds of Formula VII as described herein. Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.

2-Aminoquinoline melanin-concentrating hormone (MCH)1R antagonists

A series of 2-aminoquinoline compounds was prepared and evaluated in MCH1R binding and functional antagonist assays. Small dialkyl, methylalkyl, methylcycloalkyl, and cyclic amines were tolerated at the quinoline 2-position. The in vivo efficacy of compound 12 was explored and compared to that of a related inactive analog to determine their effects on food intake and body weight in rodents.

Novel synthesis of 2-chloroquinolines from 2-vinylanilines in nitrile solvent

2-Vinyl- or heteroaryl-substituted anilines were reacted with diphosgene in acetonitrile solution via a reactive imidoyl moiety to afford the corresponding 2-chloroquinolines. Facile syntheses of nine 2-chloroquinoline derivatives from several anilines and their postulate mechanism is described. The postulate mechanism of 2-chloroquinoline formation via imidoyl moiety as a good leaving group shows that the reaction consists of the following three steps: (1) generation of phenylisocyanate, (2) quinoline ring formation, and (3) chlorination on C2 position of quinoline.

A new efficient synthesis of 6-nitroquipazine

A convenient and regioselective synthesis of 6-nitroquipazine from hydrocarbostyril in three steps is described. This synthetic route involved a nitration, a chlorination followed by aromatization, and an aromatic substitution reaction.